Abstract
The authors previously reported the clinical effect of MS-antigen in the treatment of nasal allergy as tested by a double blind test, where d-chlorpheniramine maleate was used as the placebo. The results were summarized that although no significant difference in the effectiveness was proved between the two groups immediately after the conclusion of the treatment, a significant difference was observed 4 weeks after the conclusion of treatment (P<0.05).
The authors recently, 3-4 years after the previous test, conducted a follow-up study on the 71 cases which were judged effective in the previous test.
Of the 71 cases, 43 cases (25 cases in MS-antigen group and 18 cases in placebo group) were located.
The continuance of the effect after 3-4 years was confirmed in 44% or 11 cases out of 25, and 17% or 3 out of 18 in the placebo group, which was proved significant statistically (α=0.06).
It was also revealed that relapse of the nasal symptoms in the MS-antigen treated group was seen within 20 months after the conclusion of the treatment and none relapsed after 21 months.
